TY - JOUR
T1 - Association between the valine/leucine247 polymorphism of β2-glycoprotein i and susceptibility to anti-phospholipid syndrome
T2 - A meta-analysis
AU - Lee, Y. H.
AU - Choi, S. J.
AU - Ji, J. D.
AU - Song, G. G.
N1 - Funding Information:
This study was supported by a grant from Korea University Medical Center.
PY - 2012/7
Y1 - 2012/7
N2 - Objective: The objective of this paper is to explore whether the valine/leucine247 (Val/Leu247) polymorphism of β2-glycoprotein I (β2GPI) confers susceptibility to anti-phospholipid syndrome (APS) and thrombosis and predicts positivity for anti-β2GPI antibodies. Methods: A meta-analysis was conducted on the associations between the β2GPI Val/Leu247 polymorphism and susceptibility to APS and thrombosis and positivity for anti-β2GPI. Results: A total of 1507 patients with APS and 1450 controls in 12 comparative studies were included in this meta-analysis. Meta-analysis of the β2GPI Val/Leu247 polymorphism showed significant associations between the β2GPI Val allele and APS, thrombosis, and anti-β2GPI positivity (odds ratio (OR) 1.316, 95% confidence interval (CI) 1.068-1.621, p=0.010; OR 1.908, 95% CI 1.195-3.046, p=0.007; OR 1.630, 95% CI 1.018-2.609, p=0.042, respectively). A direct comparison between anti-β2GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β2GPI-positive patents (OR 1.514, 95% CI 1.017-1.253, p=0.041). Furthermore, a direct comparison between thrombosis-positive and -negative patients also indicated that the Val/Val+Val/Leu and the Val/Val vs. Leu/Leu genotypes of the β2GPI polymorphism were significantly elevated in patients with thrombosis (OR 2.817, 95% CI 1.200-6.610, p=0.017; OR 3.312, 95% CI 1.338-8.200, p=0.010, respectively). Conclusion: This meta-analysis shows that the β2GPI Val/Leu247 polymorphism is associated with susceptibility to APS and thrombosis and with anti-β2GPI positivity.
AB - Objective: The objective of this paper is to explore whether the valine/leucine247 (Val/Leu247) polymorphism of β2-glycoprotein I (β2GPI) confers susceptibility to anti-phospholipid syndrome (APS) and thrombosis and predicts positivity for anti-β2GPI antibodies. Methods: A meta-analysis was conducted on the associations between the β2GPI Val/Leu247 polymorphism and susceptibility to APS and thrombosis and positivity for anti-β2GPI. Results: A total of 1507 patients with APS and 1450 controls in 12 comparative studies were included in this meta-analysis. Meta-analysis of the β2GPI Val/Leu247 polymorphism showed significant associations between the β2GPI Val allele and APS, thrombosis, and anti-β2GPI positivity (odds ratio (OR) 1.316, 95% confidence interval (CI) 1.068-1.621, p=0.010; OR 1.908, 95% CI 1.195-3.046, p=0.007; OR 1.630, 95% CI 1.018-2.609, p=0.042, respectively). A direct comparison between anti-β2GPI-positive and -negative patients revealed that the frequency of the Val allele was significantly higher in anti-β2GPI-positive patents (OR 1.514, 95% CI 1.017-1.253, p=0.041). Furthermore, a direct comparison between thrombosis-positive and -negative patients also indicated that the Val/Val+Val/Leu and the Val/Val vs. Leu/Leu genotypes of the β2GPI polymorphism were significantly elevated in patients with thrombosis (OR 2.817, 95% CI 1.200-6.610, p=0.017; OR 3.312, 95% CI 1.338-8.200, p=0.010, respectively). Conclusion: This meta-analysis shows that the β2GPI Val/Leu247 polymorphism is associated with susceptibility to APS and thrombosis and with anti-β2GPI positivity.
KW - Anti-phospholipid syndrome
KW - meta-analysis
KW - polymorphism
KW - β2-glycoprotein I
UR - http://www.scopus.com/inward/record.url?scp=84861816626&partnerID=8YFLogxK
U2 - 10.1177/0961203312440348
DO - 10.1177/0961203312440348
M3 - Article
C2 - 22399073
AN - SCOPUS:84861816626
SN - 0961-2033
VL - 21
SP - 865
EP - 871
JO - Lupus
JF - Lupus
IS - 8
ER -